These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12594893)

  • 1. Prevention and treatment of multiple organ dysfunction syndrome: lessons learned and future prospects.
    Dunn DL
    Surg Infect (Larchmt); 2000; 1(3):227-36; discussion 236-7. PubMed ID: 12594893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bactericidal and endotoxin neutralizing activity of a peptide derived from Limulus antilipopolysaccharide factor.
    Weiss CA; Wasiluk KR; Kellogg TA; Dunn DL
    Surgery; 2000 Aug; 128(2):339-44. PubMed ID: 10923014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interchangeable endotoxin-binding domains in proteins with opposite lipopolysaccharide-dependent activities.
    Schumann RR; Lamping N; Hoess A
    J Immunol; 1997 Dec; 159(11):5599-605. PubMed ID: 9548502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin.
    Marra MN; Wilde CG; Collins MS; Snable JL; Thornton MB; Scott RW
    J Immunol; 1992 Jan; 148(2):532-7. PubMed ID: 1729370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A peptide derived from human bactericidal/permeability-increasing protein (BPI) exerts bactericidal activity against Gram-negative bacterial isolates obtained from clinical cases of bovine mastitis.
    Chockalingam A; McKinney CE; Rinaldi M; Zarlenga DS; Bannerman DD
    Vet Microbiol; 2007 Nov; 125(1-2):80-90. PubMed ID: 17560054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel endotoxin antagonist attenuates tumor necrosis factor-alpha secretion.
    Dahlberg PS; Acton RD; Battafarano RJ; Uknis ME; Ratz CA; Johnston JW; Haseman JR; Gray BH; Dunn DL
    J Surg Res; 1996 Jun; 63(1):44-8. PubMed ID: 8661170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting bacterial endotoxin: two sides of a coin.
    Bosshart H; Heinzelmann M
    Ann N Y Acad Sci; 2007 Jan; 1096():1-17. PubMed ID: 17405910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sepsis and organ failure--its pathogenesis and treatment].
    Hanasawa K; Kodama M
    Nihon Geka Gakkai Zasshi; 1998 Aug; 99(8):523-7. PubMed ID: 9789288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonistic effects of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein on lipopolysaccharide-induced cytokine release by mononuclear phagocytes. Competition for binding to lipopolysaccharide.
    Dentener MA; Von Asmuth EJ; Francot GJ; Marra MN; Buurman WA
    J Immunol; 1993 Oct; 151(8):4258-65. PubMed ID: 8409400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A synthetic peptide derived from bactericidal/permeability-increasing protein neutralizes endotoxin in vitro and in vivo.
    Jiang Z; Hong Z; Guo W; Xiaoyun G; Gengfa L; Yongning L; Guangxia X
    Int Immunopharmacol; 2004 Apr; 4(4):527-37. PubMed ID: 15099530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biology of endotoxin antagonism.
    Lazaron V; Dunn DL
    World J Surg; 2002 Jul; 26(7):790-8. PubMed ID: 11948366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Limulus anti-LPS factor-derived peptide modulates cytokine gene expression and promotes resolution of bacterial acute infection in mice.
    Vallespi MG; Alvarez-Obregón JC; Rodriguez-Alonso I; Montero T; Garay H; Reyes O; Araña MJ
    Int Immunopharmacol; 2003 Feb; 3(2):247-56. PubMed ID: 12586605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gram-negative bacterial sepsis and sepsis syndrome.
    Dunn DL
    Surg Clin North Am; 1994 Jun; 74(3):621-35. PubMed ID: 8197534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody therapy for gram-negative sepsis: principles, applications, and controversies.
    Mehra IV; Gottlieb JE; Nash DB
    Pharmacotherapy; 1993; 13(2):128-34. PubMed ID: 8469619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic induced endotoxin release and clinical sepsis: a review.
    Holzheimer RG
    J Chemother; 2001 Nov; 13 Spec No 1(1):159-72. PubMed ID: 11936361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of endotoxin neutralization by synthetic cationic compounds.
    Andrä J; Gutsmann T; Garidel P; Brandenburg K
    J Endotoxin Res; 2006; 12(5):261-77. PubMed ID: 17059690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C1 inhibitor suppresses the endotoxic activity of a wide range of lipopolysaccharides and interacts with live gram-negative bacteria.
    Mejia P; Davis AE
    Shock; 2012 Aug; 38(2):220-5. PubMed ID: 22576004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A functional variant of lipopolysaccharide binding protein predisposes to sepsis and organ dysfunction in patients with major trauma.
    Zeng L; Gu W; Zhang AQ; Zhang M; Zhang LY; Du DY; Huang SN; Jiang JX
    Ann Surg; 2012 Jan; 255(1):147-57. PubMed ID: 22167001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for antibiotic-mediated endotoxin release as a contributing factor to lethality in experimental gram-negative sepsis.
    Morrison DC; Bucklin SE
    Scand J Infect Dis Suppl; 1996; 101():3-8. PubMed ID: 9060044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.